BCHE and serum lipopolysaccharide activity: Previous publications have indicated that the activation of central cholinergic signaling and the central action of cholinesterase inhibitors activate the cholinergic anti-inflammatory pathway (CAP) and alleviate systemic inflammation in inflammatory bowel disease or murine endotoxemia [4–8].